Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Clinical trial NCT05484622 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05484622
- Sponsor
- Institut de Recherches Internationales Servier
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-20
- Primary completion
- 2026-02-12
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.